Liver and digestive diseases
26 public biotech companies we cover are developing treatments for MASH, ulcerative colitis, Crohn's disease, cholestatic liver disease and other digestive conditions. 18 upcoming catalysts are listed below, with dates as the companies gave them.
Companies
- ABIVAX Société Anonyme (ABVX)Thesis Intact
Crohn's disease, Ulcerative colitis
- Aclaris Therapeutics (ACRS)Thesis Intact
Eosinophilic esophagitis
- Altimmune (ALT)Thesis Intact
Alcohol-associated liver disease, Metabolic dysfunction-associated steatohepatitis
- Aquestive Therapeutics (AQST)Thesis Challenged
Nausea and vomiting
- Arcus Biosciences (RCUS)Thesis Intact
Inflammatory bowel disease
- Ardelyx (ARDX)Thesis Challenged
Chronic idiopathic constipation, Irritable bowel syndrome with constipation
- Arrowhead Pharmaceuticals (ARWR)Thesis Intact
Alcohol-related liver disease, Metabolic-dysfunction associated steatohepatitis
- Assembly Biosciences (ASMB)Thesis Intact
Primary biliary cholangitis, Primary sclerosing cholangitis
- Chemomab Therapeutics (CMMB)Thesis Challenged
Nonalcoholic steatohepatitis, Primary sclerosing cholangitis
- Eledon Pharmaceuticals (ELDN)Thesis Challenged
Liver transplantation
- Equillium (EQ)Thesis Intact
Celiac disease, Ulcerative colitis
- Eupraxia Pharmaceuticals (EPRX)Thesis Intact
Eosinophilic esophagitis
- Heron Therapeutics (HRTX)Thesis Challenged
Postoperative nausea and vomiting, Chemotherapy-induced nausea and vomiting
- Inventiva (IVA)Thesis Challenged
MASH with moderate and advanced fibrosis (F2/F3), Metabolic dysfunction-associated steatohepatitis
- Ironwood Pharmaceuticals (IRWD)Thesis Intact
SBS-IF, Short bowel syndrome, Functional constipation, Dependent on parenteral support
- Lipocine (LPCN)Thesis Broken
Cirrhosis
- Lucid Diagnostics (LUCD)Thesis Challenged
GERD, Esophageal precancer
- Mesoblast (MESO)Thesis Intact
Life-threatening gastrointestinal bleeding
- Palatin Technologies (PTN)Thesis Challenged
Ulcerative colitis
- Palisade Bio (PALI)Thesis Intact
Crohn's disease, Ulcerative colitis
- ProQR Therapeutics (PRQR)Thesis Intact
Biliary atresia, Cholestatic disease, Cholestatic liver disease, Metabolic Associated Steatohepatitis, and 1 more
- Protara Therapeutics (TARA)Thesis Intact
Parenteral support dependence
- Recursion Pharmaceuticals (RXRX)Thesis Intact
Familial adenomatous polyposis
- Sagimet Biosciences (SGMT)Thesis Intact
Metabolic dysfunction-associated steatohepatitis, Metabolic dysfunction-associated steatohepatitis cirrhosis
- Shattuck Labs (STTK)Thesis Intact
Crohn's disease, Inflammatory bowel disease
- Viking Therapeutics (VKTX)Thesis Intact
MASH
Upcoming catalysts
Firm dates · a specific day set by the company or regulator
Next 30 days
- Nov 2in 8 daysREC-4881 · Phase 1b/2 updated results · Familial adenomatous polyposis
Estimated timing · a month, quarter, half-year or year-end the company gave
Expected in November 2026
- early November 2026EQ504 · Phase 1 start · Ulcerative colitis
Expected in December 2026
- December 2026EP-104GI · Phase 2b topline results (RESOLVE) · Eosinophilic esophagitis
Expected in Q4 2026
- Q4 2026Lanifibranor · Phase 3 topline results (NATiV3) · Metabolic dysfunction-associated steatohepatitis (MASH)
- Q4 2026IV Choline Chloride · Phase 2b/3 interim results (THRIVE-3) · Parenteral support dependence
Expected in H2 2026
- 2H 2026PALI-2108 · Phase 2 start (ASCENTRA-UC) · Ulcerative colitis · moderate to severe
- H2 2026Denifanstat + Resmetirom · Phase 2 start · MASH cirrhosis · F4
Expected by end of 2026
- end of 2026Obefazimod · NDA submission · Ulcerative colitis · moderate to severe
- year-end 2026AX-0810 · Phase 1 long-term results · Cholestatic liver disease · NTCP modulation
Expected in January 2027
- early January 2027AX-0811 · CTA submission · Cholestatic disease · NTCP modulation
Expected in Q1 2027
- Q1 2027ABI-6250 · Phase 2 start · Primary biliary cholangitis · Primary sclerosing cholangitis
- Q1 2027PALI-2108 · Phase 2 start (ASCENTRA-CD) · Crohn's disease
Expected in Q2 2027
- Q2 2027EQ504 · Phase 1 topline results · Ulcerative colitis
Expected in H1 2027
- H1 2027Lanifibranor · NDA submission · MASH with moderate and advanced fibrosis (F2/F3)
- H1 2027AX-2911 · Trial start · MASH · Metabolic Associated Steatohepatitis
- H1 2027AX-0810 · Phase 2 interim results · Biliary atresia · NTCP modulation
- H1 2027SL-846 · IND submission · Inflammatory bowel disease
Expected by end of June 2027
- mid-2027Obefazimod · Phase 2b topline results (ENHANCE-CD) · Crohn's disease · moderate to severe